20:39 , Dec 7, 2016 |  BC Innovations  |  Translation in Brief

Mighty mitochondria

MDNA Life Sciences Inc. thinks circulating mitochondrial DNA holds the key to early, non-invasive detection of a host of diseases. Having launched its first mitochondrial-based diagnostic in October - a prostate cancer blood test dubbed...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Mitomics, LabCorp sales and marketing update

Mitomics granted LabCorp's Dianon Systems Inc. rights to sell Mitomics' Prostate Core Mitomic Test . The test will be performed at Mitomics' CLIA-certified laboratory. Last year, Mitomics launched the quantitative PCR assay in the U.S....
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

LabMD Inc., Mitomics sales and marketing update

Mitomics granted LabMD non-exclusive, U.S. commercialization rights to Mitomics' Prostate Core Mitomic Test . Last year, Mitomics launched the quantitative PCR assay in the U.S. to determine the presence of malignant cells via a cancerization...
07:00 , May 30, 2011 |  BC Week In Review  |  Company News

Mitomics, QDx Pathology Services Inc. sales and marketing update

QDx received non-exclusive rights from Mitomics to develop and commercialize the mitochondrial marker behind Mitomics' prostate cancer diagnostic Prostate Core Mitomic Test (PCMT), which is used to determine the presence or absence of cancerous cells....
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Mitomics sales and marketing update

Mitomics launched its Prostate Core Mitomic Test (PCMT) prostate cancer diagnostic in the U.S. The test is based on mitochondrial DNA to determine the presence or absence of cancerous cells and is available through Mitomics'...